THE OBJECTIVE IS TO DETERMINE: (1)
WHETHER ORAL CONTRACEPTIVE DRUG USE IS CASUALLY ASSOCIATED WITH THE
OCCURENCE OF CUTANEOUS MALIGNANT MELANOMA; (2) WHETHER THIS
REPORTED MALIGNANT DRUG EFFECT IS DEPENDENT OR INFLUENCED BY OTHER
KNOWN RISK FACTORS FOR THIS MALIGNANT SKIN DISEASE, E.G. SUNLIGHT
EXPOSURE AND SUN SENSITIVITY OR COLOR OF SKIN. ONE HUNDRED AND
FIFTY CASES AND 300 CONTROLS ARE BEING ASCERTAINED IN THE LOS
ANGELES AND SAN FRANCISCO BAY AREA
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.